Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Sarcoma

983 - A phase II/III trial of hafnium oxide nanoparticles activated by radiotherapy in the treatment of locally advance soft tissue sarcoma of the extremity and trunk wall


19 Oct 2018


Proffered paper session - Sarcoma



Tumour Site

Soft Tissue Sarcomas


Sylvie Bonvalot


S. Bonvalot1, P.L. Rutkowski2, J. Thariat3, S. Carrere4, M. Sunyach5, E. Saada6, P. Agoston7, A. Hong8, A. Mervoyer9, M. Rastrelli10, C. Le Pechoux11, V. Moreno12, R. Li13, B. Tiangco14, A. Casado Herraez15, A. Gronchi16, L. Mangel17, P. Hohenberger18, M. Delannes19, Z. Papai20

Author affiliations

  • 1 Surgery, Institut Curie, 75248 cedex5 - Paris/FR
  • 2 Soft Tissue/bone Sarcoma And Melanoma, The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), 02-781 - Warsaw/PL
  • 3 Radiation oncology, Centre François Baclesse, Caen/FR
  • 4 Oncological Surgery, Centre Regional De Lutte Contre Le Cancer Paul Lamarque, Montpellier/FR
  • 5 Radiation oncology, Centre Léon Bérard, Lyon/FR
  • 6 Medical Oncology, Centre Anticancer Antoine Lacassagne, 6100 - Nice/FR
  • 7 Radiation oncology, Országos Onkologiai Intézet, Budapest/HU
  • 8 Radiation oncology, Chris O'Brien Lifehouse, Camperdown/AU
  • 9 Radiation oncology, Institut de Cancerologie de l'Ouest- Rene Gauducheau, Saint-Herblain/FR
  • 10 Surgical oncology, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 11 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 12 Medical Oncology, Hospital Fundación Jimenez Diaz, 28040 - Madrid/ES
  • 13 Medical Oncology, St. Luke’s Medical Center, Quezon city/PH
  • 14 Medical Oncology, The Medical City Cancer Center, 1300 - Pasay City/PH
  • 15 Medical Oncology, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 16 Surgery, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 17 Oncotherapy, University of Pecs, 7624 - Pecs/HU
  • 18 Surgical oncology & Thoracic Surgery, Universitätsklinikum Mannheim, 68167 - Mannheim/DE
  • 19 Radiation oncology, Institut Claudius Regaud, Toulouse/FR
  • 20 Medical Centre, Hungarian Defence Forces, 1062 - Budapest/HU


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 983


NBTXR3 is a first-in-class Hafnium-Oxide nanoparticle intratumorally (IT) injected. When activated by radiotherapy (RT), it allows for a higher energy deposit than RT alone, yielding an increased tumoral cell death.

A phase I study in soft tissue sarcoma (STS) showed that a single NBTXR3 IT injection at 10% of the baseline tumor volume with preoperative RT was technically feasible with manageable toxicity and clinical activity was observed.


In this international, multicenter, randomized, open-label phase II/III study, patients (pts) with locally advanced STS of the extremity and trunk wall received either a single IT injection of NBTXR3 followed by RT or RT alone (1:1 ratio), both followed by surgical resection. RT was by Intensity Modulated RT or 3D-RT of 2Gy/25 fractions (total 50 Gy). The primary endpoint was the pathological Complete Response Rate (pCRR) defined as the percentage of pts presenting ≤5% of residual viable cancer cells (EORTC guidelines) evaluated by a blind Central Review Board. Key secondary endpoints included negative surgical margins (R0) and safety.


In the intent-to-treat full analysis set population (n=179), which included all pts who were randomized and stratified by STS histological subtype, the pCRR was 16.1% vs 7.9 (p=0.0448) and the R0 rate was 77.0% vs 64.0% (p=0.0424) for NBTXR3+RT and RT alone respectively. NBTXR3 caused injection-site pain in 12 (13.5%) pts. It was also associated with grade 3-4 acute immune reactions in 7 (7.9%) pts, but these adverse events were of short duration, manageable, and resolved spontaneously in some cases. Outside the injection, NBTXR3 was very well tolerated and its safety profile was comparable to RT alone.


NBTXR3 activated by RT was signicantly superior to RT alone and this trial met both primary and secondary endpoint with a positive safety profile. NBTXR3 represents a new option for preoperative treatment for locally advanced STS.

These data support ongoing studies investigating NBTXR3 in recurrent/metastatic HNSCC or metastatic non-small cell lung cancer [NCT03589339]; HNSCC [NCT01946867; NCT02901483]; prostate [NCT02805894], liver [NCT02721056] and rectal cancers [NCT02465593].

Clinical trial identification


Editorial Acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.